Project Grant K99HL175029
Award Date
9/1/24
Completion Date
8/31/26
Dollars Obligated
$132K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Gainesville, FL 32611, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $744,305 to the Rector & Visitors of the University of Virginia (UVA) to conduct research on the molecular physiology of PHOX2B-expressing neurons in the retrotrapezoid nucleus (RTN). The key objectives are to: Investigate how persistent expression of wild-type and disease-relevant PHOX2B mutations regulate genes critical...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $421,800.00 to Midwestern University to explore the effects of chronic intermittent hypoxia on cholinergic modulation at hypoglossal motoneurons. The project will use immunofluorescence and electrophysiology techniques to evaluate neuroanatomical and functional changes in cholinergic signaling at hypoglossal motoneurons in mice...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $480,990 to the University of Illinois to investigate the role of aerocytes, a specialized capillary endothelial cell population, in promoting alveolar epithelial regeneration following lung injury. The research aims to establish the central regulatory function of aerocyte-derived signaling, particularly the angiocrine factor...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $445,648 in funding to Mayo Clinic to support a translational training program in respiratory disease and repair. The program aims to train the next generation of basic, translational, and clinician scientists to advance respiratory medicine and restore respiratory function in disease and dysfunction. It will support 5...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $605,678 to the University of South Alabama to explore a novel mechanism regulating genome-wide mRNA expression in hypoxic lung disease. The research project, titled "A Novel Mechanism Regulating Genome-Wide mRNA Expression in Hypoxic Lung Disease," aims to investigate how hypoxia (low oxygen) activates a pathway that...
This $1,147,992 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to advance precision medicine for acute respiratory distress syndrome (ARDS) and sepsis. The award aims to address key unanswered questions about the functional immune response and pathogen drivers underlying distinct "hyperinflammatory" and "hypoinflammatory" phenotypes observed in these critical...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will provide $249,000 to the University of Wisconsin-Madison to conduct research on the neurophysiological mechanisms underlying opioid-induced airway constriction. The primary objective is to better understand how opioids, particularly fentanyl, disrupt the autonomic regulation of airway function, with the goal of developing novel therapeutic...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $564,445 Project Grant under the Cardiovascular Diseases Research Program (CFDA 93.837) to the University of Texas Health Science Center at Houston (UTHealth). The 7-year award, running from March 1, 2025 to December 31, 2031, will support UTHealth's "Hypoxia-Inflammation Program" focused on targeting hypoxia-inducible factors (HIFs) for the treatment of heart and lung diseases. The program encompasses three...
This $915,924 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to investigate how disruptions in early-life microbiome colonization can impact the development and function of lung-resident immune cells and epithelial cells, potentially contributing to respiratory diseases. The research will explore how microbial dysbiosis during infancy reprograms pathways related to lung immunity (resistance) and...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $170,543 to Virginia Commonwealth University (VCU) for a 2-year period from September 1, 2024 to August 31, 2026. The funding supports research to characterize the mechanism by which the mechanoreceptor PIEZO2 drives metabolic adaptations in response to increased lung matrix stiffness, and how these metabolic changes contribute to...